Form 4: AnaptysBio Director John Orwin Acquires 6,030 Shares Through RSU Vesting

AnaptysBio, Inc. Director John A. Orwin has acquired 6,030 shares of common stock through the vesting of restricted stock units, as reported in a recent SEC Form 4 filing.

Summary

• John A. Orwin, a Director of AnaptysBio, Inc. (ANAB), reported a change in beneficial ownership.
• On June 15, 2025, Mr. Orwin acquired 6,030 shares of AnaptysBio Common Stock.
• This acquisition resulted from the vesting of 6,030 Restricted Stock Units (RSUs) at a price of $0 per share.
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
• Following this transaction, Mr. Orwin directly beneficially owns 9,365 shares of Common Stock.
• The RSUs vested 100% on the date of the Issuer's 2025 annual meeting of shareholders, contingent on Mr. Orwin's continued service to the Issuer.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it reflects a director increasing their direct ownership in the company through a pre-scheduled equity compensation event, aligning their interests with shareholders. It is a routine transaction and not indicative of significant new information.

Positives

• The acquisition of shares by a director through RSU vesting indicates a pre-planned compensation event, reflecting the director's continued equity stake in the company.
• The increase in the director's direct beneficial ownership to 9,365 shares aligns the director's interests with those of shareholders.

Future Outlook

The document indicates that the vesting of the Restricted Stock Units was contingent upon the reporting person's provision of service to the Issuer on the date of the Issuer's 2025 annual meeting of shareholders.

Industry Context

This Form 4 filing is a routine disclosure of an insider's equity transaction, common across all industries, particularly in biotechnology where equity compensation is a standard component of executive and director remuneration.

Related Party Transactions

• The transaction involves the vesting of Restricted Stock Units (RSUs) granted by AnaptysBio, Inc. to its director, John A. Orwin, which is a form of compensation and a standard related-party transaction in the context of corporate governance.

Stakeholder Impact

• Shareholders: The transaction increases the director's direct ownership, potentially signaling continued confidence and aligning management interests with shareholder value.
• Employees: No direct impact on general employees is indicated by this filing.

Key Dates

Keywords

AnaptysBio, ANAB, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Common Stock, Director Ownership, Equity Compensation